Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,202,574
  • Shares Outstanding, K 114,859
  • Annual Sales, $ 251,250 K
  • Annual Income, $ 75,410 K
  • 60-Month Beta 1.54
  • Price/Sales 4.82
  • Price/Cash Flow 16.10
  • Price/Book 4.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.18
  • Number of Estimates 2
  • High Estimate 0.19
  • Low Estimate 0.17
  • Prior Year 0.14
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.55 +8.80%
on 05/31/19
10.77 -3.53%
on 06/20/19
+0.08 (+0.78%)
since 05/24/19
3-Month
9.55 +8.80%
on 05/31/19
12.87 -19.27%
on 05/06/19
-0.78 (-6.98%)
since 03/22/19
52-Week
9.14 +13.68%
on 02/05/19
19.48 -46.66%
on 12/12/18
-5.67 (-35.31%)
since 06/22/18

Most Recent Stories

More News
Corcept (CORT) Down 11.3% Since Last Earnings Report: Can It Rebound?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CORT : 10.39 (-0.76%)
Oversold Conditions For Corcept Therapeutics (CORT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

CORT : 10.39 (-0.76%)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Corcept, Mobile TeleSystems, Healthcare Services, and American Renal and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Corcept Therapeutics Incorporated, Mobile TeleSystems PJSC, Healthcare Services...

ARA : 7.01 (-0.57%)
CORT : 10.39 (-0.76%)
MBT : 9.26 (+1.54%)
HCSG : 29.65 (-2.15%)
CRBP, NIO & CORT Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Class Action

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints...

CORT : 10.39 (-0.76%)
CRBP : 7.10 (-3.40%)
NIO : 2.66 (+0.76%)
DEADLINE MONDAY REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept"...

CORT : 10.39 (-0.76%)
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CORT, HCSG, BA and NOK

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...

CORT : 10.39 (-0.76%)
NOK : 5.05 (-2.13%)
HCSG : 29.65 (-2.15%)
BA : 374.97 (+0.84%)
DEADLINE TODAY: Rosen Law Firm Reminds Corcept Therapeutics Incorporated Investors of Important May 13th Deadline in Securities Class Action Lawsuit - CORT

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Corcept Therapeutics Incorporated (NASDAQ: CORT) from August 2, 2017 through February 5, 2019, inclusive (the...

CORT : 10.39 (-0.76%)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In NIO, CORT, HCSG or FCHS To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, encourages investors in the following companies to contact the firm:

CORT : 10.39 (-0.76%)
NIO : 2.66 (+0.76%)
FCHS : 0.2708 (-3.29%)
HCSG : 29.65 (-2.15%)
DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corcept Therapeutics Incorporated and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT)...

CORT : 10.39 (-0.76%)
Corcept Therapeutics (CORT) Q1 Earnings Top Estimates

Corcept (CORT) delivered earnings and revenue surprises of 11.11% and -3.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

CORT : 10.39 (-0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade CORT with:

Business Summary

Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol....

See More

Key Turning Points

2nd Resistance Point 10.70
1st Resistance Point 10.58
Last Price 10.39
1st Support Level 10.31
2nd Support Level 10.16

See More

52-Week High 19.48
Fibonacci 61.8% 15.53
Fibonacci 50% 14.31
Fibonacci 38.2% 13.09
Last Price 10.39
52-Week Low 9.14

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar